Although this study has limitations (eg, small sample size, only dry fabrics tested), our results suggest that clothing provides better protection against UVA than sunscreens. Moreover, as all garments tested, except the white cotton shirt, afforded [50 UPF protection with a CW of [370 nm, these garments appeared to effectively protect against UVB and UVA. Given the superior broad spectrum UV protection of most clothing tested relative to sunscreens, dermatologists should emphasize the importance of clothing as a first line of sun protection to their patients.
Multiple melanonychia striata as a sign of connective tissue disorders To the Editor: Melanonychia striata in multiple fingernails (multi-MS) is extremely rare. [1] [2] [3] A study in a Chinese population reported that melanonychia striata was detected in 2 fingernails in only 0.003% of The critical wavelengths calculated for commercially available clothing and previously established critical wavelengths for commercially available sunscreens by Diffey et al. 2 The clothing products tested had superior ultraviolet A coverage to all sunscreens except avobenzone. PABA, Para-aminobenzoic acid; PBSA, phenylbenzimidazole sulfonic acid; TiO 2 , titanium dioxide; ZnO, zinc oxide. the total population, and there was no case with melanonychia striata in [2 fingernails. 4 Many associations related to multi-MS have been reported: Peutz-Jeghers, Cronkhite-Canada, Addison, and Laugier-Hunziker syndromes; secondary exogenous nail pigmentation due to chronic trauma, pecan nuts, dyes, chemicals, chemotherapy and HIV immunodeficiency; lichen planus; onychomycotic matricoma; dermatopathia pigmentosa reticularis; GalliGalli disease; Dowling-Degos disease; chronic kidney disease; cancer; fungus; candida melanonychia; lupus; melanoma; splinter hemorrhages of the nails due to porphyria or hemophilia; pachyonychia; and Darier disease. [1] [2] [3] However, most available data are based on case reports. Thus, we retrospectively assessed the number of nails with melanonychia striata, underlying disorders, and cutaneous changes in the fingers of patients with melanonychia striata who visited our hospital during 2011-2016. Statistical analysis was performed by using Pearson chi-squared test and the ManneWhitney U test.
We identified 97 (27 male, 70 female) patients, all of whom were Japanese. The mean age of the patients was 45.3 (range 5-80) years. Melanonychia striata was observed in a single nail in 79 patients (81.4%) and in multiple nails in 18 patients (18.6%) ( Table I) . Of the 18 patients with multi-MS, 7 patients had melanonychia striata in both fingernails and toenails, including 3 patients with Raynaud phenomenon (RP) and nail-fold bleeding (NFB), 2 with onychomycosis, and 2 with no findings (Fig 1) . Five of 97 patients with melanonychia striata had connective tissue diseases (CTDs) that had already been diagnosed before visiting. The CTDs observed included Sj€ ogren syndrome (SjS; n ¼ 2), an overlap of SjS and systemic sclerosis (SSc; n ¼ 1), systemic lupus erythematosus (n ¼ 1), and rheumatoid arteritis (n ¼ 1). Other related disorders were onychomycosis (n ¼ 2) and chronic hepatitis (n ¼ 1), and 1 patient had a history of treatment with tegafur/uracil for laryngeal cancer. Of the 18 patients with multi-MS, RP and NFB were observed in 6 patients (35.3%) and 4 patients (23.5%), respectively. The mean number of fingernails with melanonychia striata was higher in patients with RP (5.3, range 2-10) and NFB (3.75, range 2-8) than those without these signs (2.1, range 2-3), although the difference was not significant. Anti-nuclear antibody was present in the 4 patients with SjS, systemic lupus erythematosus, or SSc but not in the patient with rheumatoid arteritis. Two patients strongly suspected of having localized SSc showed RP or NFB, although these patients were negative for anti-nuclear antibody (Table I) . No cases of CTDs, RP, or NFB were found among the patients with melanonychia striata in a single nail.
In the present study, multi-MS was observed in one sixth of melanonychia striata cases, and one third of the patients with multi-MS had CTDs or RP. No patients with melanonychia striata in only a single nail had these conditions. The findings suggested 
ANA, Anti-nuclear antibody; MO, melanonychia; NFB, nail-fold bleeding; NS, not studied; RA, rheumatoid arteritis; RF, rheumatoid factor; RP, Raynaud phenomenon; RNP, ribonuclear protein; SjS, Sj€ ogren syndrome; SLE, systemic lupus erythematosus; Sm, smith protein; SSc, systemic sclerosis. *Normal range: \15 IU/mL. y Diagnosis of patient was uncertain.
Fig 1.
Hands of 66-year-old Japanese woman with melanonychia striata in multiple fingernails. She had Raynaud phenomenon, systemic sclerosis of fingers, and fingernails with elongated cuticles.
that CTDs and RP could be important underlying disorders related to multi-MS. The causative pathogenesis of multi-MS in CTDs is unclear. In the present study, multi-MS was seen in association with SjS and SSc, which were frequently accompanied by RP and NFB, which could reflect microvascular damage. 5 Thus, stress caused by ischemia could increase the melanin in the nail matrix.
This was a retrospective study with a small number of Japanese patients visiting a university hospital. To determine the real frequency of CTDs in patients with multi-MS, it is necessary to assess a comparable population sample of the same age without other diseases, syndromes, or connective tissue diseases. However, CTDs and RP should receive more attention as underlying disorders associated with multi-MS. It is important to carefully evaluate the skin around the nails by dermoscopic examination and to assess the history of RP when patients with multi-MS are identified. To the Editor: Acitretin in individual case reports and intralesional Candida antigen have shown promising efficacy in the treatment of recalcitrant warts; however, a combination of both agents has not been previously studied. 1,2 Herein, we evaluate the efficacy and adverse effects of this combination therapy versus either agent alone in the treatment of recalcitrant warts.
The study included 108 adult patients presenting with multiple recalcitrant warts (warts of [2 years duration that did not respond to at least 2 different modalities). Patients were divided into 3 equal groups: group A received a combination of acitretin (0.5 mg/kg/day until complete clearance or for a maximum duration of 3 months) and intralesional Candida antigen (0.2 mL at 2-week intervals until complete clearance or for a maximum of 5 sessions), group B received acitretin alone, and group C received intralesional Candida antigen alone.
All patients completed the study. Complete clearance of warts was observed in 24 patients (66.7%) of group A, 14 patients (38.9%) of group B, and 12 patients (33.3%) of group C (Fig 1, A-C ). There was a statistically significant difference in the therapeutic response between the combination therapy group and the other 2 groups. Adverse effects were mild or transient and included pain during injection, itching, edema, flu-like symptoms, and cheilitis. After a 6-month follow-up period, recurrence of warts was observed in 4 patients of isolated acitretin group. Due to the relatively high incidence of wart recalcitrance and the frequent recurrence associated with the use of monotherapies, attempts have been made to combine therapies to increase the efficacy, decrease the adverse effects, and reduce the recurrence rate. 3 In the combined acitretin and Candida antigen group, complete clearance of warts was achieved in 66.7% of the studied patients. In the acitretin alone group, complete clearance was achieved in 38.9% of the patients. In the Candida antigen group, complete response was achieved in 33.3% of the patients. This rate of success was lower than that reported by many other authors, 1,4 a finding that might be attributed to differences in the number of studied patients and the type of treated warts.
The superiority of the combination therapy over either agent alone might be attributed to the combined effects of both acitretin and Candida antigen. Candida antigen injection stimulates the production of T helper 1 cytokines that activate cytotoxic and natural killer cells to eradicate human papilloma virus infection. 5 Acitretin modulates epithelial cell
